TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: new focal cerebral ischaemic lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Spike in IOP of 10 mmHg or more
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Inspiratory flow rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Emotional symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in headache severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in risk of atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: resolution of systemic inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in triglyceride levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: improvement in total rhinitis symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average nightly adherence to CPAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: initial CPAP treatment acceptance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: brachial artery flow-mediated dilation improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ≥15% reduction in LV end-systolic volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uptake of SMC medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Baseline StO2 of affected hands
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in ISQ values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean combined fetal weights
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intrauterine growth retardation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time for completion of expansion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Overall clinical success rate at 3 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recurrent nightmares
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: associated symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Suppression of interferon-gamma (IFN-gamma)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Postoperative incidence of atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Postoperative incidence of supraventricular tachycardia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Average ventricular premature contraction per hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: heart Dmean
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: lung V5 Gy[ RBE ]
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Severe neurological deficit (NIHSS score ≥ 15)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: glucose disposal rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: non-oxidative glucose metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: glycolytic flux
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Post operative bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for infiltration anaesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Risk of penetration-aspiration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of post-swallow pharyngeal residues
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relative cerebral blood volume (rCBV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of contraception
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Knowledge about family planning methods
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Desire to limit births
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: ADRI rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: % predicted FEV(1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rate of initiation of potentially inappropriate prescriptions
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of discontinuation of potentially inappropriate prescriptions
Endpoint domain: Adverse events/effects
Primary endpoint: Refractive change at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Likelihood of selling to obviously intoxicated patrons
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total symptom scores of severe symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CMS symptom scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dyspnea, palpitation, and headache index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fat content reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decreased proteinuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Marital adjustment levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: arrhythmia free interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resting SpO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time Trial (TT) duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Caregiver knowledge improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Caregiver satisfaction with discharge instructions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Response to GTN
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean total AHI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduced odds of condomless sex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum C-reactive protein level at 48 hours after TKA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rectosigmoid motility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: symptoms in patients with IBS
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Days on antibiotics
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Western Ontario Rotator Cuff index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement on the Vineland Adaptive Behaviors Scale socialization subscale
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: u-NTX
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: serum P1NP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Qualitative assessment of overall preference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effective concentration (C(eff)) of methotrexate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in post-bronchodilator therapy FEV(1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Pulmonary vascular smooth muscle tension regulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ex-smoker rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Annual point prevalence quit rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of imaging modality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total lesion count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Il-6 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Il-1ra levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clearance of SOM230
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elimination half-life of SOM230
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EC50 for GH inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of subsequent first stroke
Endpoint domain: Mortality/survival
Primary endpoint: Pain during IUD deployment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall pain rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain 10 minutes after IUD placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trapezius relaxation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Mean change of LDL-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Symptom relief rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge regarding appropriate antibiotic use
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: number of amphetamine-negative urine samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of continuous abstinence
Endpoint domain: Mortality/survival
Primary endpoint: reduction in craving levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Primary and repeat amputation rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Detection of malnourished subjects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: allergen-induced sneezes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: congestion score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: secretion weights
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of hypersensitivity reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Improvement in balance performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in rigidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life impact due to erectile dysfunction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Improvement in erosion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: working memory and attention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Significant liver fibrosis prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Significant inflammation prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee joint problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Energy costs of level walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of participants falling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of death, recurrent myocardial infarction, stroke or revascularization of the infarct‐related artery (IRA) at 1 year
Endpoint domain: Mortality/survival
Primary endpoint: Significant pain relief (>or=50%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge about risk management options
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Acceptability of educational material
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: duration of all signs and symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Species richness in oral samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of Moraxella catarrhalis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy in identifying emotions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reaction time (RA time)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decision-making accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence rate at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: total time for the 100-kJ work interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of antibiotic treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in hemoglobin level 24 hours after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: BDI-II score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FIBSER score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of paroxetine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for acetaminophen to control pain
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Clearance of infected cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: mean maximum inspiratory pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: mean 6-minute walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: baseline dyspnoea index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: timely MMR vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: scheduled one‐year visit
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Neutralization titers against JEV strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Fasting concentrations of ghrelin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Inhibition of LNCaP prostate cancer cell growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean absolute relative difference (ARD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of SG values within ±20% of reference values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 31-day mortality
Endpoint domain: Mortality/survival
Primary endpoint: Small bowel obstruction
Endpoint domain: Adverse events/effects
Primary endpoint: Reported helpfulness of mnemonic
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Asking direct questions about partner violence
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Mean time to full crusting of herpes zoster lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coronary vasoreactivity to intracoronary acetylcholine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Serum levels of high‐sensitivity CRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum levels of adiponectin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Postprandial AA bioavailability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: accuracy of understanding of fracture anatomy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADAS-Cog change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Hemodynamic fluctuations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: serum 25 OH vitamin D levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: decarboxylated osteocalcin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Progression time of the disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to implantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interval between implantation and peak midluteal E2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Affected arm activity measured by the arm accelerometer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: coaching minutes required per patient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: IgG4 and IgE-blocking factor levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Adverse events leading to premature discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: risk of falls and fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DeltaUCCR changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Arterial lactate concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: CVD risk assessment completion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion of FOBT within 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fasting triglyceride (TG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean VLDL size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ankle-brachial index (ABI) < 0.90
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: CCS angina Class I/II
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normal perfusion in thallium stress test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness in treating dyslipoproteinaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: SANDE and SPEED symptomology scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: non-invasive tear film breakup time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ocular Demodex and bacterial load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: AUC and C(max) of EE exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(∞), AUC(last), and C(max) of LVG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WBC count and serum interleukin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Burn depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive bacterial cultures
Endpoint domain: Adverse events/effects
Primary endpoint: headache
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: facial pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of radiocontrast nephropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Absolute changes in serum creatinine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Size of the posterior third of the corpus callosum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Gingival bleeding tendency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiologic progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of questions answered correctly
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: coping efficacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patency rate of infarct-related artery (IRA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total hospitalization time
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Time to publication
Endpoint domain: Resource use
Endpoint subdomain: Other resource use